Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.
Schöffski
P
P
Garfield
D H
DH
Hercbergs
A
A
Wolter
P
P
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012107:Research Design; D000077210:Sunitinib; D016896:Treatment Outcome
D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib